{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:35:46Z","timestamp":1766486146793,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017018","name":"Goteborgs Universitet Wallenbergcentrum for molekylar och translationell medicin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejso.2023.06.026","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T17:53:50Z","timestamp":1688406830000},"page":"106974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Population-based prognostic instrument (SweMR 2.0) for melanoma-specific survival - An ideal tool for individualised treatment decisions for Swedish patients"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4988-6346","authenticated-orcid":false,"given":"Johan","family":"Lyth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasmus","family":"Mikiver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kari","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Ingvar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-0355","authenticated-orcid":false,"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolin","family":"Isaksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2023.06.026_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2016.02.029","article-title":"Prognostic instrument for survival outcome in melanoma patients: based on data from the population-based Swedish Melanoma Register","volume":"59","author":"Lyth","year":"2016","journal-title":"Eur J Cancer"},{"author":"Lyth","key":"10.1016\/j.ejso.2023.06.026_bib2"},{"key":"10.1016\/j.ejso.2023.06.026_bib3","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2023.06.026_bib4","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2023.06.026_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2023.06.026_bib6","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2023.06.026_bib7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2023.06.026_bib8","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2023.06.026_bib9","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2023.06.026_bib10","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2023.06.026_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.07.001","article-title":"Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial","volume":"119","author":"Eggermont","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2023.06.026_bib12","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2023.06.026_bib13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ejso.2023.06.026_bib14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","article-title":"The Swedish cause of death register","volume":"32","author":"Brooke","year":"2017","journal-title":"Eur J Epidemiol"},{"year":"2017","series-title":"AJCC cancer staging manual","author":"Amin","key":"10.1016\/j.ejso.2023.06.026_bib15"},{"key":"10.1016\/j.ejso.2023.06.026_bib16","first-page":"67","volume":"vol. 45","author":"van Buuren","year":"2011"},{"year":"1987","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","key":"10.1016\/j.ejso.2023.06.026_bib17"},{"key":"10.1016\/j.ejso.2023.06.026_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-017-0404-7","article-title":"Methods for significance testing of categorical covariates in logistic regression models after multiple imputation: power and applicability analysis","volume":"17","author":"Eekhout","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejso.2023.06.026_bib19","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.ejso.2023.06.026_bib20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/sim.1621","article-title":"A\u00a0new measure of prognostic separation in survival data","volume":"23","author":"Royston","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.ejso.2023.06.026_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement","volume":"13","author":"Collins","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.ejso.2023.06.026_bib22","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/jdv.14280","article-title":"Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register","volume":"31","author":"Lyth","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejso.2023.06.026_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12885-015-1024-4","article-title":"Prognostic survival model for people diagnosed with invasive cutaneous melanoma","volume":"15","author":"Baade","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2023.06.026_bib24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jamcollsurg.2011.12.027","article-title":"A\u00a0novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American joint committee on cancer model","volume":"214","author":"Callender","year":"2012","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.ejso.2023.06.026_bib25","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1002\/cncr.24565","article-title":"The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death","volume":"115","author":"Chen","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2023.06.026_bib26","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1245\/s10434-016-5212-5","article-title":"Critical assessment of clinical prognostic tools in melanoma","volume":"23","author":"Mahar","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2023.06.026_bib27","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1002\/cncr.24542","article-title":"Why cancer at the primary site and in the lymph nodes contributes to the risk of cancer death","volume":"115","author":"Michaelson","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2023.06.026_bib28","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1002\/cncr.24592","article-title":"How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death","volume":"115","author":"Michaelson","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2023.06.026_bib29","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1245\/s10434-010-1050-z","article-title":"Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database","volume":"17","author":"Soong","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2023.06.026_bib30","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1245\/s10434-018-6370-4","article-title":"Variability in predictions from online tools: a demonstration using internet-based melanoma predictors","volume":"25","author":"Zabor","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2023.06.026_bib31","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ejca.2015.07.039","article-title":"Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study","volume":"51","author":"Crocetti","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2023.06.026_bib32","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ejca.2014.07.016","article-title":"Uses of cancer registries for public health and clinical research in Europe: results of the European Network of Cancer Registries survey among 161 population-based cancer registries during 2010\u20132012","volume":"51","author":"Siesling","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832300567X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832300567X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:52:39Z","timestamp":1760061159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879832300567X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S074879832300567X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2023.06.026","relation":{},"ISSN":["0748-7983"],"issn-type":[{"type":"print","value":"0748-7983"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population-based prognostic instrument (SweMR 2.0) for melanoma-specific survival - An ideal tool for individualised treatment decisions for Swedish patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2023.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106974"}}